Cargando…
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
BACKGROUND: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate and commonl...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266273/ https://www.ncbi.nlm.nih.gov/pubmed/34258590 http://dx.doi.org/10.1016/S2665-9913(21)00212-5 |
_version_ | 1783719910598246400 |
---|---|
author | Mahil, Satveer K Bechman, Katie Raharja, Antony Domingo-Vila, Clara Baudry, David Brown, Matthew A Cope, Andrew P Dasandi, Tejus Graham, Carl Lechmere, Thomas Malim, Michael H Meynell, Freya Pollock, Emily Seow, Jeffery Sychowska, Kamila Barker, Jonathan N Norton, Sam Galloway, James B Doores, Katie J Tree, Timothy I M Smith, Catherine H |
author_facet | Mahil, Satveer K Bechman, Katie Raharja, Antony Domingo-Vila, Clara Baudry, David Brown, Matthew A Cope, Andrew P Dasandi, Tejus Graham, Carl Lechmere, Thomas Malim, Michael H Meynell, Freya Pollock, Emily Seow, Jeffery Sychowska, Kamila Barker, Jonathan N Norton, Sam Galloway, James B Doores, Katie J Tree, Timothy I M Smith, Catherine H |
author_sort | Mahil, Satveer K |
collection | PubMed |
description | BACKGROUND: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate and commonly used targeted biological therapies, compared with healthy controls. Given the roll-out of extended interval vaccination programmes to maximise population coverage, we present findings after the first dose. METHODS: In this cohort study, we recruited consecutive patients with a dermatologist-confirmed diagnosis of psoriasis who were receiving methotrexate or targeted biological monotherapy (tumour necrosis factor [TNF] inhibitors, interleukin [IL]-17 inhibitors, or IL-23 inhibitors) from a specialist psoriasis centre serving London and South East England. Consecutive volunteers without psoriasis and not receiving systemic immunosuppression who presented for vaccination at Guy's and St Thomas' NHS Foundation Trust (London, UK) were included as the healthy control cohort. All participants had to be eligible to receive the BNT162b2 vaccine. Immunogenicity was evaluated immediately before and on day 28 (±2 days) after vaccination. The primary outcomes were humoral immunity to the SARS-CoV-2 spike glycoprotein, defined as neutralising antibody responses to wild-type SARS-CoV-2, and spike-specific T-cell responses (including interferon-γ, IL-2, and IL-21) 28 days after vaccination. FINDINGS: Between Jan 14 and April 4, 2021, 84 patients with psoriasis (17 on methotrexate, 27 on TNF inhibitors, 15 on IL-17 inhibitors, and 25 on IL-23 inhibitors) and 17 healthy controls were included. The study population had a median age of 43 years (IQR 31–52), with 56 (55%) males, 45 (45%) females, and 85 (84%) participants of White ethnicity. Seroconversion rates were lower in patients receiving immunosuppressants (60 [78%; 95% CI 67–87] of 77) than in controls (17 [100%; 80–100] of 17), with the lowest rate in those receiving methotrexate (seven [47%; 21–73] of 15). Neutralising activity against wild-type SARS-CoV-2 was significantly lower in patients receiving methotrexate (median 50% inhibitory dilution 129 [IQR 40–236]) than in controls (317 [213–487], p=0·0032), but was preserved in those receiving targeted biologics (269 [141–418]). Neutralising titres against the B.1.1.7 variant were similarly low in all participants. Cellular immune responses were induced in all groups, and were not attenuated in patients receiving methotrexate or targeted biologics compared with controls. INTERPRETATION: Functional humoral immunity to a single dose of BNT162b2 is impaired by methotrexate but not by targeted biologics, whereas cellular responses are preserved. Seroconversion alone might not adequately reflect vaccine immunogenicity in individuals with immune-mediated inflammatory diseases receiving therapeutic immunosuppression. Real-world pharmacovigilance studies will determine how these findings reflect clinical effectiveness. FUNDING: UK National Institute for Health Research. |
format | Online Article Text |
id | pubmed-8266273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-82662732021-07-09 The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study Mahil, Satveer K Bechman, Katie Raharja, Antony Domingo-Vila, Clara Baudry, David Brown, Matthew A Cope, Andrew P Dasandi, Tejus Graham, Carl Lechmere, Thomas Malim, Michael H Meynell, Freya Pollock, Emily Seow, Jeffery Sychowska, Kamila Barker, Jonathan N Norton, Sam Galloway, James B Doores, Katie J Tree, Timothy I M Smith, Catherine H Lancet Rheumatol Articles BACKGROUND: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate and commonly used targeted biological therapies, compared with healthy controls. Given the roll-out of extended interval vaccination programmes to maximise population coverage, we present findings after the first dose. METHODS: In this cohort study, we recruited consecutive patients with a dermatologist-confirmed diagnosis of psoriasis who were receiving methotrexate or targeted biological monotherapy (tumour necrosis factor [TNF] inhibitors, interleukin [IL]-17 inhibitors, or IL-23 inhibitors) from a specialist psoriasis centre serving London and South East England. Consecutive volunteers without psoriasis and not receiving systemic immunosuppression who presented for vaccination at Guy's and St Thomas' NHS Foundation Trust (London, UK) were included as the healthy control cohort. All participants had to be eligible to receive the BNT162b2 vaccine. Immunogenicity was evaluated immediately before and on day 28 (±2 days) after vaccination. The primary outcomes were humoral immunity to the SARS-CoV-2 spike glycoprotein, defined as neutralising antibody responses to wild-type SARS-CoV-2, and spike-specific T-cell responses (including interferon-γ, IL-2, and IL-21) 28 days after vaccination. FINDINGS: Between Jan 14 and April 4, 2021, 84 patients with psoriasis (17 on methotrexate, 27 on TNF inhibitors, 15 on IL-17 inhibitors, and 25 on IL-23 inhibitors) and 17 healthy controls were included. The study population had a median age of 43 years (IQR 31–52), with 56 (55%) males, 45 (45%) females, and 85 (84%) participants of White ethnicity. Seroconversion rates were lower in patients receiving immunosuppressants (60 [78%; 95% CI 67–87] of 77) than in controls (17 [100%; 80–100] of 17), with the lowest rate in those receiving methotrexate (seven [47%; 21–73] of 15). Neutralising activity against wild-type SARS-CoV-2 was significantly lower in patients receiving methotrexate (median 50% inhibitory dilution 129 [IQR 40–236]) than in controls (317 [213–487], p=0·0032), but was preserved in those receiving targeted biologics (269 [141–418]). Neutralising titres against the B.1.1.7 variant were similarly low in all participants. Cellular immune responses were induced in all groups, and were not attenuated in patients receiving methotrexate or targeted biologics compared with controls. INTERPRETATION: Functional humoral immunity to a single dose of BNT162b2 is impaired by methotrexate but not by targeted biologics, whereas cellular responses are preserved. Seroconversion alone might not adequately reflect vaccine immunogenicity in individuals with immune-mediated inflammatory diseases receiving therapeutic immunosuppression. Real-world pharmacovigilance studies will determine how these findings reflect clinical effectiveness. FUNDING: UK National Institute for Health Research. Elsevier Ltd 2021-07-08 /pmc/articles/PMC8266273/ /pubmed/34258590 http://dx.doi.org/10.1016/S2665-9913(21)00212-5 Text en © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Mahil, Satveer K Bechman, Katie Raharja, Antony Domingo-Vila, Clara Baudry, David Brown, Matthew A Cope, Andrew P Dasandi, Tejus Graham, Carl Lechmere, Thomas Malim, Michael H Meynell, Freya Pollock, Emily Seow, Jeffery Sychowska, Kamila Barker, Jonathan N Norton, Sam Galloway, James B Doores, Katie J Tree, Timothy I M Smith, Catherine H The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study |
title | The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study |
title_full | The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study |
title_fullStr | The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study |
title_full_unstemmed | The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study |
title_short | The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study |
title_sort | effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the covid-19 vaccine bnt162b2: a cohort study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266273/ https://www.ncbi.nlm.nih.gov/pubmed/34258590 http://dx.doi.org/10.1016/S2665-9913(21)00212-5 |
work_keys_str_mv | AT mahilsatveerk theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT bechmankatie theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT raharjaantony theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT domingovilaclara theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT baudrydavid theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT brownmatthewa theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT copeandrewp theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT dasanditejus theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT grahamcarl theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT lechmerethomas theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT malimmichaelh theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT meynellfreya theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT pollockemily theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT seowjeffery theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT sychowskakamila theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT barkerjonathann theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT nortonsam theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT gallowayjamesb theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT dooreskatiej theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT treetimothyim theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT smithcatherineh theeffectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT mahilsatveerk effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT bechmankatie effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT raharjaantony effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT domingovilaclara effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT baudrydavid effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT brownmatthewa effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT copeandrewp effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT dasanditejus effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT grahamcarl effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT lechmerethomas effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT malimmichaelh effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT meynellfreya effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT pollockemily effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT seowjeffery effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT sychowskakamila effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT barkerjonathann effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT nortonsam effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT gallowayjamesb effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT dooreskatiej effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT treetimothyim effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy AT smithcatherineh effectofmethotrexateandtargetedimmunosuppressiononhumoralandcellularimmuneresponsestothecovid19vaccinebnt162b2acohortstudy |